128 related articles for article (PubMed ID: 38458890)
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract][Full Text] [Related]
2. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
[TBL] [Abstract][Full Text] [Related]
3. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
[TBL] [Abstract][Full Text] [Related]
4. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
[TBL] [Abstract][Full Text] [Related]
6. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract][Full Text] [Related]
8. Rare germline genetic variants and risk of aggressive prostate cancer.
Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
[TBL] [Abstract][Full Text] [Related]
9. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
[TBL] [Abstract][Full Text] [Related]
10. Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer.
Nguyen-Dumont T; Dowty JG; MacInnis RJ; Steen JA; Riaz M; Dugué PA; Renault AL; Hammet F; Mahmoodi M; Theys D; Tsimiklis H; Severi G; Bolton D; Lacaze P; Sebra R; Schadt E; McNeil J; Giles GG; Milne RL; Southey MC
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33804961
[TBL] [Abstract][Full Text] [Related]
11. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson Q; Brook MN; Dadaev T; Wakerell S; Saunders EJ; Muir K; Neal DE; Giles GG; MacInnis RJ; Thibodeau SN; McDonnell SK; Cannon-Albright L; Teixeira MR; Paulo P; Cardoso M; Huff C; Li D; Yao Y; Scheet P; Permuth JB; Stanford JL; Dai JY; Ostrander EA; Cussenot O; Cancel-Tassin G; Hoegel J; Herkommer K; Schleutker J; Tammela TLJ; Rathinakannan V; Sipeky C; Wiklund F; Grönberg H; Aly M; Isaacs WB; Dickinson JL; FitzGerald LM; Chua MLK; Nguyen-Dumont T; ; Schaid DJ; Southey MC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2021 Aug; 4(4):570-579. PubMed ID: 33436325
[TBL] [Abstract][Full Text] [Related]
12. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
[TBL] [Abstract][Full Text] [Related]
13. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Kote-Jarai Z; Leongamornlert D; Saunders E; Tymrakiewicz M; Castro E; Mahmud N; Guy M; Edwards S; O'Brien L; Sawyer E; Hall A; Wilkinson R; Dadaev T; Goh C; Easton D; ; Goldgar D; Eeles R
Br J Cancer; 2011 Oct; 105(8):1230-4. PubMed ID: 21952622
[TBL] [Abstract][Full Text] [Related]
14. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
[TBL] [Abstract][Full Text] [Related]
15. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
[TBL] [Abstract][Full Text] [Related]
16. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
[TBL] [Abstract][Full Text] [Related]
17. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
18. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
[TBL] [Abstract][Full Text] [Related]
19. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Mitra A; Fisher C; Foster CS; Jameson C; Barbachanno Y; Bartlett J; Bancroft E; Doherty R; Kote-Jarai Z; Peock S; Easton D; ; Eeles R
Br J Cancer; 2008 Jan; 98(2):502-7. PubMed ID: 18182994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
